The last 2 decades have seen great progress in understanding the pathogenesis of cold
agglutinin disease (CAD) and development of effective therapies. Cold agglutinins can …

Introduction Cold agglutinin disease (CAD) is a difficult-to-treat autoimmune hemolytic
anemia and B cell lymphoproliferative disorder associated with fatigue, acrocyanosis, and a …

Cold antibody-mediated autoimmune hemolytic anemia (cAIHA) is a rare disease, usually
related to an underlying indolent clonal B-cell lymphoproliferative disorder. Jalink and …

Introduction During the last decades, the pathogenesis of cold agglutinin disease (CAD) has
been well elucidated and shown to be complex. Several documented or investigational …

Introduction Autoimmune hemolytic anemia (AIHA) is considered a chronic disease, with an
overall good prognosis. However, recent reports indicate pre‐mature mortality. Causes of …

Therapies for cold agglutinin disease have been directed at the pathogenic B-cell clone.
Sutimlimab, a monoclonal antibody that targets C1s, is the first complement inhibitor to be …

Background: Cold agglutinin disease (CAD) is a rare disorder, affecting 15% of patients with
autoimmune hemolytic anemia. Few studies have assessed CAD symptoms and their impact …

Abstract Purpose of Review Cold-antibody mediated autoimmune hemolytic anemia (cAIHA)
is subclassified as cold agglutinin disease (CAD), secondary cold agglutinin syndrome …

Sutimlimab, a complement inhibitor, has recently been approved in Japan for treating cold
agglutinin disease (CAD). We report the safety and efficacy of sutimlimab in Japanese …

1. Garban F, Guyard A, Labussiere H, Bulabois CE, Marchand T, Mounier C, et al.
Comparison of the hemostatic efficacy of pathogen-reduced platelets vs untreated platelets …